Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges

Drug Delivery

Volumn 17, Issue 6, 2010, Pages 419-425

  Torne, Satyen J ^a   Ansari, Khalid A ^a   Vavia, Pradeep R ^a   Trotta, Francesco ^b   Cavalli, Roberta ^b  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Complexation; Cyclodextrin; Nanosponges; Paclitaxel; Taxol

Indexed keywords

BETA CYCLODEXTRIN DERIVATIVE; NANOPARTICLE; NANOSPONGE; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER; POLYMER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; DRY POWDER; FREEZE DRYING; MALE; MAXIMUM PLASMA CONCENTRATION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOAVAILABILITY; BLOOD; CHEMISTRY; CRYSTALLIZATION; HALF LIFE TIME; INTESTINE ABSORPTION; KINETICS; METABOLIC CLEARANCE RATE; SOLUBILITY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; CRYSTALLIZATION; DRUG CARRIERS; DRUG COMPOUNDING; HALF-LIFE; INTESTINAL ABSORPTION; KINETICS; MALE; METABOLIC CLEARANCE RATE; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

EID: 77954253351     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717541003777233     Document Type: Article

References (24)

1. Bardelmeijer, H.A., Beijnen, J.H., Brouwer, K.R., Rosing, H., Nooijen, W.J., Schellens, J.H., van Tellingen, O. (2000). Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin Cancer Res. 6:4416-4421
2. Cavalli, R., Trotta, F. (2009). Characterization and applications of new hyper-cross-linked cyclodextrins. Compos Interface. 16:39-48.
3. Cavalli, R., Trotta, F., Tumiatti, W. (2006). Cyclodextrin-based nano-sponges for drug delivery. Incl Phenom Macrocycl Chem. 56:209-213
4. Diehl, K.H., Hull, R., Morton, D., Pfster, R., Rabemampianina, Y., Smith, D., Vidal, J.M., Vorstenbosch, C. (2001). A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol. 21:15-23.
5. Doyle, L.A., Ross, V. (2003). Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 22:7340-7358
6. Gao, P., Rush, B.D., Pfund, W.P., Huang, T., Bauer, J.M., Morozowich, W., Kuo, M.S., Hageman, M.J. (2003). Development of a supersatura-ble SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J Pharm Sci. 92:2386-2398
7. Harris, J.W., Rahman, A., Kim, B.R., Guengerich, F.P., Collins, J.M. (1994). Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54:4026-4035
8. Higgins, C.F. (1992). ABC transporters: from microorganisms to man. Annu Rev Cell Biol. 8:67-113.
9. Huisman, M.T., Chhatta, A.A., Tellingen, O., Beijnen, J.H., Schinkel, A.H. (2005). MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 116:824-829
10. Kruijtzer, C.M., Beijnen, J.H., Schellens, J.H. (2002). Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist. 7:516-530
11. Malingre, M.M., Beijnen, J.H., Schellens, J.H. (2001). Oral delivery of taxanes. Invest New Drugs. 19:155-162
12. Meerum, J.M., Terwogt, M.M., Malingre, J.H., Beijnen, W.W., Huinink, H., Rosing, F.J., Koopman, van Tellingen, Swart, O.M., Schellens, J.H. (1999). Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res. 5:3379-3384
13. Rahman, A., Korzekwa, K.R., Grogan, J., Gonzalez, F.J., Harris, J.W. (1994). Selective biotransformation of taxol to 6 alpha-hydrox-ytaxol by human cytochrome P4502C8. Cancer Res. 54:5543-5546
14. Rowinsky, E.K. (1993). Clinical pharmacology of Taxol. J Natl Cancer Inst Monogr. 15:25-37.
15. Rowinsky, E.K., Eisenhauer, E.A., Chaudhry, V., Arbuck, S.G., Donehower, R.C. (1993). Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol. 20:1-15.
16. Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A.H., Smit, J.W., Meijer, D.K., Borst, P., Nooijen, W.J., Beijnen, J.H., van Tellingen, O. (1997). Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA. 94:2031-2035
17. Sutherland, L., Ebner, T., Burchell, B. (1993). Te expression of UDP glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs. Biochem Pharmacol. 45:295-301.
18. Swaminathan, S., Pastero, L., Serpe, L., Troota, F., Vavia, P., Aquilano, D., Trotta, M., Zara, G., Cavalli, R. (2009). Cyclodextrin-based nano-sponges encapsulating camptothecin: physicochemical characterization, stability and cytotoxicity. Eur J Pharm Biopharm. 74:193-201.
19. Trotta, F., Tumiatti, W. (2003). Cross-linked polymers based on cyclodextrin for removing polluting agents. World patent: WO 03/085002.
20. van Asperen, J., Tellingen, O., van der Valk, M.A., Rozenhart, M., Beijnen, J.H. (1998). Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin Cancer Res. 4:2293-2297
21. Vavia, P.R., Swaminathan, S., Trotta, F., Torne, S.J. (2007). Formulation of beta cyclodextrin based nanosponges of itraconazole. Incl Phenom Macrocycl Chem. 57:89-94.
22. Walle, T., Walle, U.K., Kuma, G.N., Bhalla, K.N. (1995). Taxol metabolism and disposition in cancer patients. Drug Metab Disp. 23:506-512
23. Wang, S., Monagle, J., Mcnulty, C., Putnam, D., Chen, H. (2004). Determination of P-glycoprotein inhibition by excipients and their combinations using an integrated high-throughput process. J Pharm Sci. 93:2755-2767
24. Zuylen, L., Verweij, J., Sparreboom, A. (2001). Role of formulation vehicles in taxane pharmacology. Invest New Drugs. 19:125-141